Compare Illumina, Inc. (ILMN) vs Meta Platforms Inc (META) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Meta Platforms Inc — how do they compare? Illumina, Inc. trades at $189.79 (market cap $27.94B), while Meta Platforms Inc trades at $647.77 (market cap $1.64T). The key difference: Meta Platforms Inc is far larger — about 58.7× Illumina, Inc.'s market cap, and Meta Platforms Inc pays a 0.33% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | META | |
|---|---|---|
Market Cap | $27.94B | $1.64T |
Sector | Health | Media |
52-Week High | $194.33 | $790.00 |
52-Week Low | $91.00 | $525.72 |
Enterprise Value | $29.33B | $1.65T |
Volume | — | 24,093,972 |
Dividend Yield | — | 0.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
META stock trades at $653.33, up 1.13% in the last session, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, including Q1 2026 EPS of $10.44 versus $6.70 expected. Revenue grew to $201.0 billion in 2025, with a net income margin of 30.08%. Recent news highlights the launch of its Muse Spark AI model and a $21 billion deal with CoreWeave, driving positive sentiment.
Outlook remains positive with a consensus price target of $817.32, implying 25% upside. Key opportunities include AI monetization and sustained revenue growth, while risks involve regulatory lawsuits and high capital expenditures. Analyst consensus is strongly bullish with 79% buy ratings, but investors should monitor legal developments and competitive pressures in the social media and AI sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →
